ProtoKinetix, Incorporated announced that it has selected two formulations of its Anti-Aging Glycopeptide (AAGP?) product to be advanced into preclinical efficacy testing for the topical treatment of dry eye disease and ocular inflammation. The selection follows a seven-month formulation development program conducted by Catalent, in which the Active Pharmaceutical Ingredient (API) was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix?s needs. The efficacy testing will be conducted by EyeCRO of Oklahoma City. This study should be completed by mid to late January 2022. The resulting lead formulation will then undergo extensive Good Laboratory Practice (GLP) toxicology examination, to prepare a submission for the U.S. FDA for its approval to conduct clinical trials.